BR9607541A - Tratamento de doenças que tem por causa o fator de crescimento da citoquina - Google Patents
Tratamento de doenças que tem por causa o fator de crescimento da citoquinaInfo
- Publication number
- BR9607541A BR9607541A BR9607541A BR9607541A BR9607541A BR 9607541 A BR9607541 A BR 9607541A BR 9607541 A BR9607541 A BR 9607541A BR 9607541 A BR9607541 A BR 9607541A BR 9607541 A BR9607541 A BR 9607541A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- cytokine growth
- pyridone
- substituted
- growth factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39796295A | 1995-03-03 | 1995-03-03 | |
| PCT/US1996/002737 WO1996027374A1 (en) | 1995-03-03 | 1996-03-04 | Treatment of cytokine growth factor caused disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9607541A true BR9607541A (pt) | 1997-12-23 |
Family
ID=23573420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9607541A BR9607541A (pt) | 1995-03-03 | 1996-03-04 | Tratamento de doenças que tem por causa o fator de crescimento da citoquina |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0813409B1 (pt) |
| JP (1) | JPH11501911A (pt) |
| AT (1) | ATE265851T1 (pt) |
| AU (1) | AU697742B2 (pt) |
| BR (1) | BR9607541A (pt) |
| CA (1) | CA2214531C (pt) |
| DE (1) | DE69632396T2 (pt) |
| ES (1) | ES2220975T3 (pt) |
| MX (1) | MX9706689A (pt) |
| WO (1) | WO1996027374A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716632A (en) * | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US6114353A (en) | 1995-03-03 | 2000-09-05 | Margolin; Solomon B. | Compositions and method for treatment of lymphomas, leukemias, and leiomyomas |
| ATE360419T1 (de) * | 1995-09-19 | 2007-05-15 | Solomon B Margolin | Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer |
| KR19980020379A (ko) * | 1996-09-09 | 1998-06-25 | 비. 마르골린 솔로몬 | 사이토킨 성장인자로 인한 질병의 치료방법 |
| ES2221365T3 (es) * | 1998-03-17 | 2004-12-16 | Solomon B. Margolin | Composiciones y metodos topicos antisepticos. |
| EP1242084B1 (en) * | 2000-01-24 | 2006-07-05 | MARGOLIN, Solomon B. | Treatment of breast carcinomas, astrocytomas, melanomas and related tumors |
| AU2001230605A1 (en) * | 2000-02-09 | 2001-08-20 | Shionogi And Co., Ltd. | Apoptosis inhibitor |
| US7825133B2 (en) * | 2003-11-14 | 2010-11-02 | Shanghai Genomics, Inc. | Derivatives of pyridone and the use of them |
| ES2600460T3 (es) | 2005-05-10 | 2017-02-09 | Intermune, Inc. | Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés |
| PE20080714A1 (es) * | 2006-06-05 | 2008-07-31 | Novartis Ag | DERIVADOS HETEROCICLICOS COMO MODULADORES DE LA ACTIVIDAD DE LA ESTEARIL-CoA-DESATURASA |
| CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
| EP2670242B1 (en) * | 2011-01-31 | 2022-03-16 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US8697753B1 (en) | 2013-02-07 | 2014-04-15 | Polichem Sa | Method of treating onychomycosis |
| CN110452216B (zh) | 2014-04-02 | 2022-08-26 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4052509A (en) * | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
| US4042699A (en) * | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
| JPH02215719A (ja) * | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
| US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| BR9406461A (pt) * | 1993-05-07 | 1996-01-30 | Solomon Begelfor Margolin | Composições e métodos para a reparação e prevenção de les~es fibróticas |
-
1996
- 1996-03-04 ES ES96909547T patent/ES2220975T3/es not_active Expired - Lifetime
- 1996-03-04 WO PCT/US1996/002737 patent/WO1996027374A1/en active IP Right Grant
- 1996-03-04 DE DE69632396T patent/DE69632396T2/de not_active Expired - Fee Related
- 1996-03-04 JP JP8526928A patent/JPH11501911A/ja not_active Ceased
- 1996-03-04 AU AU53005/96A patent/AU697742B2/en not_active Expired
- 1996-03-04 AT AT96909547T patent/ATE265851T1/de not_active IP Right Cessation
- 1996-03-04 CA CA002214531A patent/CA2214531C/en not_active Expired - Lifetime
- 1996-03-04 BR BR9607541A patent/BR9607541A/pt not_active Application Discontinuation
- 1996-03-04 EP EP96909547A patent/EP0813409B1/en not_active Expired - Lifetime
-
1997
- 1997-09-03 MX MX9706689A patent/MX9706689A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU697742B2 (en) | 1998-10-15 |
| CA2214531C (en) | 2009-01-20 |
| JPH11501911A (ja) | 1999-02-16 |
| MX9706689A (es) | 1998-06-30 |
| ES2220975T3 (es) | 2004-12-16 |
| CA2214531A1 (en) | 1996-09-12 |
| ATE265851T1 (de) | 2004-05-15 |
| EP0813409B1 (en) | 2004-05-06 |
| EP0813409A4 (en) | 1999-01-07 |
| DE69632396D1 (de) | 2004-06-09 |
| AU5300596A (en) | 1996-09-23 |
| WO1996027374A1 (en) | 1996-09-12 |
| DE69632396T2 (de) | 2005-05-04 |
| EP0813409A1 (en) | 1997-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9607541A (pt) | Tratamento de doenças que tem por causa o fator de crescimento da citoquina | |
| YU47543B (sh) | Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita | |
| DE69634609D1 (de) | Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten | |
| MD990262A (en) | Method of prophylaxis or delay of the Alzheimer disease start and therapeutic product effective for prevention of said disease | |
| ATE267798T1 (de) | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung | |
| RU95109905A (ru) | Композиции в жидком, полутвердом, твердом, гелеобразном или пастообразном виде и способ лечения заболеваний полости рта | |
| DE69132688D1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| NO20053077L (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
| BG101118A (en) | Therapeutical compounds | |
| FI935847A0 (fi) | L-DOPA-esterkompositioner | |
| PT1207756E (pt) | Utilizacao de espinosade ou de uma formulacao que compreende espinosade | |
| ZA967880B (en) | Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha | |
| ATE179888T1 (de) | Ophthalmische zubereitung zur behandlung oder prävention von trockenem auge und krankheiten, die dadurch verursacht werden, enthaltend 12- sulfodehydroabietsäure | |
| CA2157142A1 (en) | Treatment of diseases caused by sebaceous gland disorders | |
| UA35611C2 (uk) | Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри | |
| ATE133859T1 (de) | Pharmazeutische zubereitungen mit verzögerter freisetzung zur behandlung periodontaler erkrankungen | |
| DK164441C (da) | Anvendelse af et piperidinderivat til fremstilling af et farmaceutisk praeparat til behandling af smertetilstande | |
| BG105275A (en) | Tan-1057 derivatives | |
| ATE157871T1 (de) | Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind | |
| EP0744176A3 (en) | Methods for inhibiting bone loss | |
| ATE316379T1 (de) | Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen | |
| BG103905A (en) | New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine | |
| DE69816808D1 (de) | Somatostatin agoniste zur reduzierung von körpergewicht | |
| CA2429793A1 (en) | Interferon therapeutic effect enhancer | |
| PT1231908E (pt) | Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |